1 Departments of Physiology and Pharmacology, Brody School of Medicine at East Carolina University, Greenville, North Carolina 27858; and 2 Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Intratracheal administration of interleukin-10 (IL-10) has been reported to inhibit allergic inflammation but augment airway hyperresponsiveness (AHR). In the present study, airway and smooth muscle responsiveness to methacholine (MCh) were compared in wild-type (WT) and IL-10-deficient (IL-10-KO) mice to investigate the role of endogenous IL-10 in AHR development. Naive WT and IL-10-KO mice exhibited similar dose-dependent increases in airway resistance (Raw) to intravenous MCh. Sensitization and challenge with ragweed (RW) induced a twofold increase in responsiveness to intravenous MCh in WT mice, but hyperresponsiveness was not observed in similarly treated IL-10-KO mice. Likewise, tracheal rings from RW-sensitized and -challenged WT mice exhibited a fourfold greater responsiveness to MCh than IL-10-KO tracheal preparations. Measurements of airway constriction by whole body plethysmography further supported the Raw and tracheal ring data (i.e., AHR was not observed in the absence of IL-10). Interestingly, factors previously implicated in the development of AHR, including IL-4, IL-5, IL-13, IgA, IgG1, IgE, eosinophilia, and lymphocyte recruitment to the airways, were upregulated in the IL-10-KO mice. Treatment with recombinant murine IL-10 at the time of allergen challenge reduced the magnitude of inflammation but reinstated AHR development in IL-10-KO mice. Adoptive transfer of mononuclear splenocytes to IL-10-sufficient severe combined immunodeficient mice indicated that lymphocytes were an important source of the IL-10 impacting AHR development. These results provide evidence that IL-10 expression promotes the development of allergen-induced smooth muscle hyperresponsiveness.
bronchial hyperresponsiveness; asthma; eosinophilia; interleukin-10
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
INTERLEUKIN (IL)-10
is an inhibitory cytokine produced by keratinocytes, macrophages, and B
and T lymphocytes (6, 18, 23). The inhibitory properties
of IL-10 are diverse and include blockade of tumor necrosis factor-
signaling (19, 26), downregulation of major
histocompatibility complex (MHC) class II, CD80, and CD86
expression (3, 11, 16), and instability of cytokine mRNA
(16). Consistent with these immune-regulatory properties, IL-10 has been shown to downregulate neutrophil and eosinophil influx
into the lungs following allergen challenge in mice (27).
Development of airway hyperresponsiveness (AHR) in murine models of asthma is dependent on development of Th2-mediated inflammation. Specifically, IL-4, IL-5, eosinophils, and Th2 lymphocytes have all been implicated in the development of AHR (13). IL-10 is also categorized as a Th2 cytokine (15) but downregulates allergic inflammation as well as Th1 responses. IL-10 levels in bronchoalveolar lavage (BAL) fluid (BALF) increase gradually following allergen challenge (24) and appear to be involved in the resolution of allergic inflammation (1). Consistent with this hypothesis, instillation of recombinant murine IL-10 (rmIL-10) into the airways of BALB/c mice at the time of allergen challenge reduces IL-4 and IL-5 concentrations in BALF and subsequent recruitment of eosinophils to the airways (24, 27). Despite the reduction of Th2 inflammatory responses, instillation of IL-10 into the airways does not reduce AHR but rather increases methacholine (MCh) responsiveness (24).
In this study, the development of AHR following ragweed (RW) allergen challenge was compared in IL-10-deficient (IL-10-KO) and wild-type (WT) C57BL/6 mice to test the hypothesis that IL-10 reduces airway inflammation concurrent with an augmentation of AHR. The results demonstrate that, in the absence of IL-10, AHR to MCh exposure does not occur despite upregulation of Th2 inflammation. In addition, instillation of rmIL-10 at the time of RW challenge induces AHR development while reducing multiple inflammatory components by ~50% in IL-10-KO mice. These data support a dual role for IL-10 as an anti-inflammatory signal that independently augments AHR.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animals. Male C57BL/6J WT, IL-10-KO C57BL/6J, and B6.CB.17 scid [severe combined immunodeficient (SCID)] mice 6-10 wk old were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained by the Department of Comparative Medicine at the Brody School of Medicine at East Carolina University (Greenville, NC). All experimental procedures were approved by the Brody School of Medicine Animal Care and Use Committee.
Allergic sensitization of C57BL/6J WT and IL-10-KO mice. Mice were sensitized by two intraperitoneal injections of RW (83 µg/injection, Lot 56-129; endotoxin content <2.3 ng/mg; Greer Laboratories, Lenoir, NC) in 25 µl of Imject Alum (Pierce, Rockford, IL) and 75 µl of PBS. Injections were given 4 days apart. Seven days after the second intraperitoneal injection, mice were anesthetized with 90 mg/kg ketamine and 10 mg/kg xylazine and challenged by intratracheal administration of 8 µg of RW in PBS.
Inflammation and airway reactivity were evaluated in separate groups of animals on day 14 (i.e., 72 h after allergen challenge). The mice were anesthetized with 90 mg/kg ketamine and 10 mg/kg xylazine and challenged by intratracheal instillation of 8 µg of RW in 100 µl of PBS. For protocols calling for reconstitution of IL-10 levels in IL-10 KO mice, rmIL-10 (R&D Systems, Minneapolis, MN) was administered intratracheally (it) on day 11 concomitant with allergen challenge. IL-10 was mixed with the RW challenge solution to achieve a dose of 1 ng per animal.BALF cell counts and cytokine determinations. Animals were anesthetized with ketamine (90 mg/kg body wt) and xylazine (10 mg/kg body wt), and the lungs were lavaged with two 0.75-ml aliquots of PBS to evaluate inflammation. The BALF cells and supernatants were collected by centrifugation at 800 g for 5 min. The recovered cells were resuspended in a constant volume, and total cell counts were determined with a hemacytometer. Differential cell counts were performed on cytocentrifuged preparations stained with Diff- Quik (Baxter Healthcare, Miami, FL). BALF supernatants were flash-frozen in liquid nitrogen at the time of collection.
Concentrations of IL-4, IL-5, IL-13, and interferon-Determination of serum immunoglobulins. Serum samples were obtained by heart puncture. Serum was diluted 40-fold with buffer (PBS + 5% BSA). Total IgE was measured by sandwich ELISA using anti-IgE and biotinylated anti-IgE antibodies (PharMingen, San Diego, CA). RW-specific IgA and IgG1 were determined by applying RW (50 µg/ml) in buffer (0.1 M sodium acetate and 1.0 M NaCl, pH 6.5) to 96-well plates overnight, followed by addition of serum samples. Detection of specific immunoglobulin isotypes was performed using biotinylated detection antibodies (PharMingen).
Adoptive transfer of WT and IL-10-KO splenoctyes into SCID mice. Prospective SCID recipient mice were primed with 8 µg of RW it 24 h before cell transfer. Splenocytes were isolated from RW-sensitized WT and IL-10-KO donor mice on day 12 of the immunization protocol described above. Mononuclear cells were further enriched by discontinuous density gradient centrifugation (30%/60% Percoll, 2,000 g for 20 min). The SCID recipients received 5 × 107 cells ip and 107 splenocytes iv. Twenty-four hours following the transfer, SCID recipients were challenged with 8 µg of RW it. Control SCID mice were primed and challenged with RW, but no cells were transferred.
Evaluation of airway reactivity. Airway reactivity was assayed using three different methodologies. First, enhanced pause (Penh) was measured in conscious animals using a whole body plethysmograph system (Buxco Electronics, Sharon, CT). At the time of study, the animals were placed in the plethysmograph chamber, and activity was allowed to stabilize for 10 min. Following equilibration, animals were exposed to nebulized saline for 2 min, and Penh was recorded for 5 min to establish a baseline. MCh was dissolved in saline to concentrations of 0.75-48 mg/ml. Animals were exposed to increasing doses of nebulized MCh for 2 min. Penh was monitored continuously for 5 min following each dose of MCh.
Second, airway resistance in anesthetized animals was measured using a Mumed pulmonary function monitoring system (PMS, Mumed, London, UK). Animals were anesthetized with 95 mg/kg ketamine and 5 mg/kg xylazine delivered by intraperitoneal injection. A 20-gauge cannula was inserted into the trachea and connected to a Fleisch 00000 pneumotachograph to monitor air flow. PE-60 tubing was inserted into the esophagus to the level of the thorax to measure transpulmonary pressure. Airway resistance (Raw) was calculated as the quotient of the changes in flow and pressure between isovolumetric points on inspiration and expiration. A 30-gauge cannula was inserted into the tail vein for injection of MCh (Sigma, St. Louis, MO). For doses <300 µg/kg, Raw was recorded for 1 min. For higher doses, Raw was recorded for 2 min after each injection of MCh to allow ample time for breathing to stabilize. Third, tracheas were excised 72 h after allergen challenge to assess smooth muscle reactivity to MCh. Extraneous tissue was removed, and the tracheas were cut into rings 2 mm wide. Rings were fixed to a strain gauge suspended in Krebs- Ringer solution containing (in mM) 115 NaCl, 0.4 KH2PO4, 2.4 K2HPO4, 25 NaHCO3, 1.2 CaCl2, and 1.2 MgCl2, in 5% CO2-95% O2. After a 1-h equilibration period, resting tension was set to 1 g. KCl was added to the bathing solution to achieve a final concentration of 50 mM. This was repeated three times, and the maximal tension to 50 mM KCl was recorded. Responses to 10Statistical analysis.
Differences between groups for BALF eosinophils, lymphocytes, IL-4 , IL-5, IL-13, and IFN- content and serum levels of IgA, IgG1, and IgE
were determined by ANOVA) A Tukey's honestly significant difference post hoc test was performed to assess significant
differences between treatment groups. Differences in dose-response
relationships were analyzed using a general linear model for full
factorial analysis of repeated measures optimized for polynomial
contrast of doses (SPSS, Chicago, IL). F value was corrected
for the correlation structure using the Greenhouse-Geisser epsilon factor.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Absence of AHR development in
RW-sensitized and -challenged IL-10-KO
mice.
AHR was first evaluated by measuring changes in Raw to
intravenous MCh in anesthetized, spontaneously breathing mice.
PBS-challenged WT and IL-10-KO mice exhibited identical
dose-response relationships (Fig.
1A).
However, following RW challenge, WT mice exhibited a 2.5-fold increase in Raw to MCh compared with PBS-challenged animals
(WT and IL-10-KO) as well as RW-challenged IL-10-KO mice (Fig.
1A, P = 0.001). These observations indicated
that IL-10 was involved in development of allergen-induced bronchial
hyperresponsiveness to MCh.
|
Reconstitution of AHR by rmIL-10 in
IL-10-deficient mice.
One nanogram of rmIL-10 was administered concomitant with RW challenge
to reconstitute IL-10 levels in the airways. In contrast to
IL-10-deficient animals, AHR was observed in IL-10-KO animals treated
with rmIL10 (Fig. 2).
|
Development of AHR in SCID mice
following adoptive transfer of WT and IL-10-KO splenocytes.
Airway reactivity was evaluated 72 h after intratracheal challenge
in SCID mice adoptively transferred with mononuclear splenocytes from
either WT or IL-10-KO mice. SCID mice receiving WT splenocytes exhibited AHR compared with control SCID mice receiving allergen challenge alone. SCID recipients receiving splenocytes from IL-10-KO mice exhibited no AHR (Fig. 3). These
results indicated that the effect of IL-10 on AHR development could be
adoptively transferred.
|
Effect of IL-10 deficiency on Th2
inflammatory parameters.
Both RW-sensitized RW-challenged WT and IL-10-KO mice exhibited
significant inflammation compared with the corresponding PBS-challenged controls. However, eosinophil and lymphocyte infiltration into the
airways 72 h following allergen challenge was greater in IL-10-KO mice than in WT animals (Table 1).
Administration of 1 ng rmIL-10 at the time of allergen challenge
reduced inflammation in IL-10-KO mice by ~50% but had minimal
effects in WT mice.
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This study demonstrates that IL-10-deficient mice fail to express RW-induced AHR to MCh. The lack of AHR was observed in vivo by measuring Raw and in vitro by measuring tension development in tracheal rings. Interestingly, multiple factors previously implicated as causative agents leading to AHR were upregulated in IL-10-deficient mice, including levels of IL-4, IL-5, IL-13, lymphocytes, and eosinophils in BALF. Reconstitution of IL-10 levels in the airways by administration of rmIL-10 at the time of challenge was sufficient to induce AHR in IL-10-KO mice while concurrently reducing other inflammatory parameters such as IgE levels in the blood, proinflammatory cytokine levels in the airways, and eosinophil infiltration into the BAL compartment. Previously published observations from this laboratory demonstrated that CD4+ Th2 lymphocytes are the predominant IL-10-producing cells in RW-stimulated splenocyte preparations (21). Taken together, the observations indicate that IL-10 production by RW-specific T cells plays an important role in development of AHR.
Since its initial characterization in 1989 by Fiorentino and colleagues (2), IL-10 has been recognized as a potent anti-inflammatory agent. Using a murine model of allergic airway disease, Zuany-Amorin and colleagues (27) demonstrated that exogenous IL-10 administered concomitant with intratracheal ovalbumin challenge inhibits airway eosinophilia. Grunig and colleagues (7) subsequently demonstrated that Aspergillus fumigatus-induced Th2 inflammation intensifies in the absence of endogenous IL-10, and Tournoy et al. (22) recently demonstrated an enhancement in airway inflammation following ovalbumin challenge in IL-10-deficient mice. Likewise, we observed enhanced Th2 inflammation in the airways of allergen-challenged IL-10-KO mice that was reversed by treatment with rmIL-10. Interestingly, Makela et al. (14) did not observe an effect of IL-10 deficiency on ovalbumin-induced Th2 inflammation within the airways. The reason for the divergence from other studies is not clear at this time.
We observed a reduction in tracheal smooth muscle responsiveness to MCh in allergic IL-10-KO animals. Similarly, Makela et al. (14) reported that tracheal smooth muscle from allergic IL-10-deficient mice was hyporesponsive to electric field stimulation and reconstitution of IL-10 expression via an adenoviral vector reconstituted the smooth muscle hyperresponsiveness. These observations are particularly relevant to the present study in two ways. First, they indicate that IL-10 does not act specifically on the cholinergic pathway. Second, in the present study, allergen-induced eosinophil influx into the airways was elevated in the IL-10-KO mouse, which allowed for the possibility that high levels of inflammation may have inhibited smooth muscle function. The fact that Makela et al. (14) observed attenuated smooth muscle responses in IL-10-KO mice in the absence of elevated Th2 inflammation argues against such a mechanism.
The inflammatory parameters measured in this study (i.e., BALF levels of IL-4, IL-5, IL-13, eosinophils, lymphocytes and serum levels of IgG1, IgA, and IgE) have been associated with AHR development. Specifically, Garlisi et al. (5) and Hogan et al. (10) independently demonstrated a correlation between airway eosinophilia and AHR in mice. Wills-Karp et al. (25) and Grunig et al. (8) have both demonstrated a role for IL-13 in allergen-induced AHR development. It has been reported that IL-5-deficient mice do not develop AHR (4) and overexpression of IL-5 in the airways of nonsensitized nonchallenged mice is sufficient to induce AHR (12). Shi and colleagues (20) have shown that inhalation of IL-4 by asthmatic individuals induces AHR. Consistent with the effect of IL-4 on B cells, the production of several immunoglobulins (IgE, IgA, and IgG1) has been shown to be elevated in the airways and serum of asthmatic individuals (17). Due to the significant elevation in all of these factors in IL-10-deficient mice, the data presented in this study suggest that, while these factors may be associated with AHR development, alone they cannot precipitate AHR development. Although the activation state of eosinophils was not addressed in these studies (as well as in this report), an earlier study demonstrated that the levels of eosinophil peroxidase and leukotriene C4 were significantly elevated within the airways of IL-10-deficient mice compared with those in WT control mice (14). Therefore, the absence of AHR development in IL-10-deficient mice also does not appear to be due to the lack of activated eosinophils within the airways of these mice.
The mechanism by which IL-10 facilitates development of AHR is not known, but the evidence indicates that it acts in concert with one or more inflammatory factors to increase smooth muscle reactivity. The following observations support this theory. First, allergic sensitization and challenge are required to observe the effect of IL-10. In WT animals, IL-10 alone has no effect on airway responses to MCh (24). Second, reactivity to MCh is similar in naive WT and IL-10-deficient mice, indicating that IL-10 does not directly stimulate airway constriction. Third, a strong correlation exists between Th2 inflammation and AHR in IL-10-sufficient animals, but that correlation breaks down in the absence of IL-10. Fourth, a similar degree of hyperresponsiveness is observed in WT mice regardless of whether the readout is Raw, Penh, or tracheal ring contraction. AHR in this model is therefore a reflection of smooth muscle activation. Fifth, as discussed above, IL-10 production by Th2 cells is critical to AHR development in this model, which indicates the need for other coincident lymphocyte-derived signals in the process. Thus AHR in this model involves the induction of smooth muscle hyperresponsiveness.
Shibata and colleagues (21) previously demonstrated that
splenocytes from RW-sensitized WT C57BL/6 mice produce IL-4, IL-5, and
IL-10 but not IFN- when stimulated with RW in vitro. Depletion of
the CD4+ cells by complement-dependent cell lysis reduces
IL-4 and IL-5 production by >80% and IL-10 production by 94%,
indicating that RW-specific Th2 cells are the major source of IL-10 in
isolated splenocytes. These observations, in combination with the
results of the adoptive transfer experiments in the present study,
indicate that IL-10 production by Th2 lymphocytes is required for
development of AHR in this model.
In summary, current evidence indicates that IL-10 downregulates allergen-induced Th2 inflammation within murine airways, yet is critical for the development of AHR in this model. While the mechanism is unclear, it is likely that IL-10 functions in concert with one or more inflammatory factors to precipitate AHR via an indirect effect on airway smooth muscle.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Don Holbert for assistance with statistical analysis.
![]() |
FOOTNOTES |
---|
This project was supported in part by National Heart, Lung, and Blood Institute Grant 5RO1-HL-50049 and an East Carolina University Brody School of Medicine Faculty Research Grant.
Address for reprint requests and other correspondence: M. R. Van Scott, Brody School of Medicine at East Carolina Univ., 6N98 Brody Bldg, Greenville, NC 27858 (E-mail: vanscottmi{at}mail.ecu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 10 February 2000; accepted in final form 19 September 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Borish, L,
Aarons A,
Rumbyrt J,
Cvietusa P,
Negri J,
and
Wenzel S.
Interleukin-10 regulation in normal subjects and patients with asthma.
J Allergy Clin Immunol
97:
1288-1296,
1996[ISI][Medline].
2.
Fiorentino, DF,
Bond MW,
and
Mosmann TR.
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.
J Exp Med
170:
2081-2095,
1989[Abstract].
3.
Flores, VP,
Reiser H,
and
Stadecker MJ.
Regulation of T helper cell responses in experimental murine schistosomiasis by IL-10. Effect on expression of B7 and B7-2 costimulatory molecules by macrophages.
J Immunol
153:
5190-5199,
1994
4.
Foster, PS,
Hogan SP,
Ramsay AJ,
Matthaei KI,
and
Young IG.
Interleukin 5 deficiency abolishes eosinophilia, airways hyperresponsiveness, and lung damage in a mouse asthma model.
J Exp Med
183:
195-201,
1996[Abstract].
5.
Garlisi, CG,
Falcone A,
Hey JA,
Paster TM,
Fernandez X,
Rizzo CA,
Minnicozzi M,
Jones H,
Billah MM,
Egan RW,
and
Umland SP.
Airway eosinophils, T cells, Th2-type cytokine mRNA, and hyperresponsiveness in response to aerosol challenge of allergic mice with previously established pulmonary inflammation.
Am J Respir Cell Mol Biol
17:
642-651,
1997
6.
Gieni, RS,
Umetsu DT,
and
DeKruyff RH.
Ly1- (CD5-) B cells produce interleukin (IL)-10.
Cell Immunol
175:
164-170,
1997[ISI][Medline].
7.
Grunig, G,
Corry DB,
Leach MW,
Seymour BW,
Kurup VP,
and
Rennick DM.
Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis.
J Exp Med
185:
1089-1099,
1997
8.
Grunig, G,
Warnock M,
Wakil AE,
Venkayya R,
Brombacher F,
Rennick DM,
Sheppard D,
Mohrs M,
Donaldson DD,
Locksley RM,
and
Corry DB.
Requirement for IL-13 independently of IL-4 in experimental asthma.
Science
282:
2261-2263,
1998
9.
Hamelmann, E,
Schwarz J,
Takeda K,
Oshiba A,
Larsen GL,
Irvin GG,
and
Gelfand EW.
Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.
Am J Respir Crit Care Med
156:
766-775,
1997
10.
Hogan, SP,
Koskinen A,
Matthaei KI,
Young IG,
and
Foster PS.
Interleukin-5-producing CD4+ T cells play a pivotal role in aeroallergen-induced eosinophilia, bronchial hyperresponsiveness, and lung damage in mice.
Am J Respir Crit Care Med
157:
210-218,
1998
11.
Knolle, PA,
Uhrig A,
Hegenbarth S,
Loser E,
Schmitt E,
Gerken G,
and
Lohse AW.
IL-10 down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules.
Clin Exp Immunol
114:
427-433,
1998[ISI][Medline].
12.
Lee, JJ,
McGarry MP,
Farmer SC,
Denzler KL,
Larson KA,
Carrigan PE,
Brenneise IE,
Horton MA,
Haczku A,
Gelfand EW,
Leikauf GD,
and
Lee NA.
Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma.
J Exp Med
185:
2143-2156,
1997
13.
Lee, NA,
and
Lee JJ.
Asthma: does IL-5 have a more provocative role?
Am J Respir Cell Mol Biol
16:
497-500,
1997[ISI][Medline].
14.
Makela, MJ,
Kanehiro A,
Borish L,
Dakhama A,
Loader J,
Joetham A,
Xing Z,
Jordana M,
Larsen GL,
and
Gelfand EW.
IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization.
Proc Natl Acad Sci USA
97:
6007-6012,
2000
15.
Moore, KW,
O'Garra A,
de Waal Malefijt R,
Vieira P,
and
Mosmann TR.
Interleukin-10.
Annu Rev Immunol
11:
165-190,
1993[ISI][Medline].
16.
Mottonen, M,
Isomaki P,
Saario R,
Toivanen P,
Punnonen J,
and
Lassila O.
Interleukin-10 inhibits the capacity of synovial macrophages to function as antigen-presenting cells.
Br J Rheumatol
37:
1207-1214,
1998[ISI][Medline].
17.
Peebles, RSJ,
Liu MC,
Adkinson NFJ,
Lichtenstein LM,
and
Hamilton RG.
Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation.
J Allergy Clin Immunol
101:
265-273,
1998[ISI][Medline].
18.
Rivas, JM,
and
Ullrich SE.
Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10.
J Immunol
149:
3865-3871,
1992
19.
Schottelius, AJ,
Mayo MW,
Sartor RB,
and
Baldwin ASJ
Interleukin-10 signaling blocks inhibitor of B kinase activity and nuclear factor
B DNA binding.
J Biol Chem
274:
31868-31874,
1999
20.
Shi, HZ,
Deng JM,
Xu H,
Nong ZX,
Xiao CQ,
Liu ZM,
Qin SM,
Jiang HX,
Liu GN,
and
Chen YQ.
Effect of inhaled interleukin-4 on airway hyperresponsiveness in asthmatics.
Am J Respir Crit Care Med
157:
1818-1821,
1998
21.
Shibata, Y,
Foster LA,
Bradfield JF,
and
Myrvik QN.
Oral administration of chitin down-regulates serum IgE levels and lung eosinophilia in the allergic mouse.
J Immunol
164:
1314-1321,
2000
22.
Tournoy, KG,
Kips JC,
and
Pauwels RA.
Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness.
Clin Exp Allergy
30:
775-783,
2000[ISI][Medline].
23.
Ullrich, SE.
Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation. Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells.
J Immunol
152:
3410-3416,
1994
24.
Van Scott, MR,
Justice JP,
Bradfield J,
Sigounas A,
Enright E,
and
Sur S.
IL-10 reduces Th2 cytokine production and eosinophilia but augments airway reactivity in allergic mice.
Am J Physiol Lung Cell Mol Physiol
278:
L667-L674,
2000
25.
Wills-Karp, M,
Luyimbazi J,
Xu X,
Schofield B,
Neben TY,
Karp CL,
and
Donaldson DD.
Interleukin-13: central mediator of allergic asthma.
Science
282:
2258-2261,
1998
26.
Yoshidome, H,
Kato A,
Edwards MJ,
and
Lentsch AB.
Interleukin-10 inhibits pulmonary NF-B activation and lung injury induced by hepatic ischemia-reperfusion.
Am J Physiol Lung Cell Mol Physiol
277:
L919-L923,
1999
27.
Zuany-Amorin, C,
Haile S,
Leduc D,
Dumarey C,
Huerre M,
Vargaftig BB,
and
Pretolani M.
Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice.
J Clin Invest
95:
2644-2651,
1995[ISI][Medline].